ACIP Human Rabies Prevention Work Group

Sharon Frey, MD
Saint Louis University School of Medicine

Advisory Committee on Immunization Practices

October 23, 2019
Work Group Members

**ACIP Members**
Sharon Frey (chair)
Lynn Bahta
José R. Romero

**Liaison Representatives**
AAP- Elizabeth Bennett
AAFP- James Stevermer
NACCHO- Matt Zahn
APhA- Karl Hess
NACI- Julie Emili and Linlu Zhao
FDA- Paula Agger and Robin Levis
NASPHV- Katie Brown and Sally Slavinski

APHL-Michael Pentella
Travel medicine- David Shlim

**Additional Subject Matter Experts**
Susan Moore
Deborah Briggs

**CDC**
Rabies Work Group leads – Jesse Blanton and Agam Rao
Division of Global Migration and Quarantine- Kristina Angelo
Immunization Safety Office – Pedro Moro
Acknowledgements

CDC Technical Work Group and Subject Matter Experts

Brett Petersen
Ryan Wallace
James Ellison
Sathesh Panayampalli
Anna Mandra
Jesse Bonwitt
Erin Whitehouse
Terms of Reference  Abbreviated

- Determine the epidemiology and burden of rabies exposures and PreP and PEP administration in the United States
- Evaluate and revise recommendations as needed for vaccination schedules, route and site of PrEP and PEP, and cost-effectiveness
- Consider evidence generated to inform the rabies recommendations of other global organizations
- Review rabies exposure risk and risk assessment guidelines for the general population and by occupational and recreational groups
Evaluate serological and monitoring recommendations including whether recommendations should differ depending on the degree of rabies risk for a person and whether adequate antibody titers are needed to confirm immunization

Consider whether recommendations should differ for healthy adults compared to immunocompromised persons and pregnant women

Update recommendations with information about the 2 rabies immune globulin products approved by the US FDA during 2018

Identify areas in need of further research for informing future vaccine and immune globulin recommendations
Timeline (Subject to Change)

**PHASE I**
- CDC: Determine scope

**PHASE II**
- Begin systematic reviews

**PHASE III**
- Begin Work Group meetings

**PHASE IV**
- Begin presenting to ACIP

**PHASE V**
- Update Guideline Recs

- **Mid 2018**
- **October 2018**
- **October 2019 to 2020**
- **2020 or 2021**
Tentative Plan for Presentations

- October 2019 – Background and introduction to PrEP issues
- February 2020
  - Detailed PrEP data including GRADE table
  - Introduction to PEP issues
- June 2020
  - Vote for PrEP topics
  - More detailed presentations about PEP
- October 2020
  - More detailed presentations about PEP vs. vote on PEP issues
Note: Current Rabies Vaccine and Immune Globulin Shortages

- The shortages should not impact patient care. Vaccine and RIG available for every patient who needs it. No modification to current practices.
- Vaccine
  - RabAvert (GlaxoSmithKline): available directly from the manufacturer
  - Imovax® (Sanofi Pasteur): Currently unavailable but expected to be available late Oct / early Nov
- RIG
  - Imogam® (Sanofi Pasteur): available directly from manufacturer
  - Kedrab™ (Kedrion Biopharma) and HyperRab® (Grifols): unchanged availability and no difficulties filling gap from Imogam

For more information: https://www.cdc.gov/rabies/resources/availability.html
October 21, 2019 GlaxoSmithKline Announcement

- GSK divesting rabies vaccine (RabAvert in U.S.) to Bavarian Nordic

- Vaccine will continue to be manufactured primarily at GSK’s Marburg, Germany site until full production is transferred to Bavarian Nordic

- No immediate impact to vaccine supply
Overview of Today’s Session

- Background - *Dr. Agam Rao (CDC/NCEZID)*

- Introduction to rabies PrEP schedule and serological monitoring by risk category in healthy nonpregnant persons and special populations - *Dr. Jesse Blanton (CDC/NCEZID)*
Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.